FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to therapy of intestinal diseases. To treat an intestinal disease (ID), in particular an irritable bowel syndrome (IBS) rifaximin in a dose of 1650 mg/day is introduced to a patient, who needs it, for 14 days. Cancelling treatment after 14 days results in the patient's stable response lasting, at least, approximately 12 weeks, within which an adequate relief of symptoms takes place. Also claimed is a set, including a container, which contains refaximin in a dose, including 1650 mg/day for 14 days and a note, in which it is described that introduction of a therapeutically efficient amount of rifaximin results in the patient's stable response, who is responsible to treatment, where stable response lasts, at least, approximately 12 weeks, within which the adequate relief of symptoms takes place.
EFFECT: application of the group of inventions makes it possible to increase efficiency of intestinal disease treatment due to the adequate relief of syndromes for approximately 12 weeks.
15 cl, 11 tbl, 6 dwg, 4 ex
